Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 75 entries
Sorted by: Best Match Show Resources per page
Toronto Sewers.

Public health papers and reports

Macdougall A.
PMID: 19600284
Public Health Pap Rep. 1886;12:41-50.

No abstract available.

Cite
Macdougall A. Toronto Sewers. Public Health Pap Rep. 1886;12:41-50
Macdougall, A. (1886). Toronto Sewers. Public health papers and reports, 1241-50.
Macdougall, A. "Toronto Sewers." Public health papers and reports vol. 12 (1886): 41-50.
Macdougall A. Toronto Sewers. Public Health Pap Rep. 1886;12:41-50. PMID: 19600284; PMCID: PMC2266134.
Copy Download .nbib Format: NLM
Fibroid Polypus.

Transactions. Edinburgh Obstetrical Society

MacDougall JA.
PMID: 29612703
Trans Edinb Obstet Soc. 1878;4:53-55.

No abstract available.

Cite
MacDougall JA. Fibroid Polypus. Trans Edinb Obstet Soc. 1878;4:53-55
MacDougall, J. A. (1878). Fibroid Polypus. Transactions. Edinburgh Obstetrical Society, 453-55.
MacDougall, John A. "Fibroid Polypus." Transactions. Edinburgh Obstetrical Society vol. 4 (1878): 53-55.
MacDougall JA. Fibroid Polypus. Trans Edinb Obstet Soc. 1878;4:53-55. PMID: 29612703; PMCID: PMC5483139.
Copy Download .nbib Format: NLM
High aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?.

Obstetric medicine

Berberich AJ, Penava D, Sun D, MacDougall A, Lum A, Van Uum S.
PMID: 32714441
Obstet Med. 2020 Jun;13(2):88-91. doi: 10.1177/1753495X18786422. Epub 2018 Nov 04.

A 36-year-old woman presented at 16 weeks' gestation with severe hypertension. In comparison to the non-pregnant reference normal ranges, potassium was 3.1-3.9 mmol/L, aldosterone 2570-3000 pmol/L (N 250-2885) renin was unsuppressed (24-76.4 ng/L (N1.7-23.9)), with aldosterone to renin ratios...

Cite
Berberich AJ, Penava D, Sun D, et al. High aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?. Obstet Med. 2018;13(2):88-91doi: 10.1177/1753495X18786422.
Berberich, A. J., Penava, D., Sun, D., MacDougall, A., Lum, A., & Van Uum, S. (2020). High aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?. Obstetric medicine, 13(2), 88-91. https://doi.org/10.1177/1753495X18786422
Berberich, Amanda J, et al. "High aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?." Obstetric medicine vol. 13,2 (2020): 88-91. doi: https://doi.org/10.1177/1753495X18786422
Berberich AJ, Penava D, Sun D, MacDougall A, Lum A, Van Uum S. High aldosterone, hypertension and adrenal adenoma in a 36-year-old pregnant patient: Is this primary aldosteronism?. Obstet Med. 2020 Jun;13(2):88-91. doi: 10.1177/1753495X18786422. Epub 2018 Nov 04. PMID: 32714441; PMCID: PMC7359658.
Copy Download .nbib Format: NLM
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.

Multiple sclerosis and related disorders

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R.
PMID: 34902760
Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04.

BACKGROUND: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging reports suggest that 1-3% B-cell repopulation facilitates seroconversion after...

Cite
Baker D, MacDougall A, Kang AS, et al. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021;57:103448doi: 10.1016/j.msard.2021.103448.
Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple sclerosis and related disorders, 57103448. https://doi.org/10.1016/j.msard.2021.103448
Baker, David, et al. "CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis." Multiple sclerosis and related disorders vol. 57 (2021): 103448. doi: https://doi.org/10.1016/j.msard.2021.103448
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04. PMID: 34902760.
Copy Download .nbib Format: NLM
Contrasting recruitment of skin-associated adipose depots during cold challenge of mouse and human.

The Journal of physiology

Kasza I, Kühn JP, Völzke H, Hernando D, Xu YG, Siebert JW, Gibson AL, Yen CE, Nelson DW, MacDougald OA, Richardson NE, Lamming DW, Kern PA, Alexander CM.
PMID: 33724479
J Physiol. 2021 Mar 16; doi: 10.1113/JP280922. Epub 2021 Mar 16.

KEY POINTS: Several distinct strategies produce and conserve heat to maintain body temperature of mammals, each associated with unique physiologies, with consequence for wellness and disease susceptibility Highly regulated properties of skin offset the total requirement for heat production...

Cite
Kasza I, Kühn JP, Völzke H, et al. Contrasting recruitment of skin-associated adipose depots during cold challenge of mouse and human. J Physiol. 2021;doi: 10.1113/JP280922.
Kasza, I., Kühn, J. P., Völzke, H., Hernando, D., Xu, Y. G., Siebert, J. W., Gibson, A. L., Yen, C. E., Nelson, D. W., MacDougald, O. A., Richardson, N. E., Lamming, D. W., Kern, P. A., & Alexander, C. M. (2021). Contrasting recruitment of skin-associated adipose depots during cold challenge of mouse and human. The Journal of physiology, . https://doi.org/10.1113/JP280922
Kasza, Ildiko, et al. "Contrasting recruitment of skin-associated adipose depots during cold challenge of mouse and human." The Journal of physiology vol. (2021). doi: https://doi.org/10.1113/JP280922
Kasza I, Kühn JP, Völzke H, Hernando D, Xu YG, Siebert JW, Gibson AL, Yen CE, Nelson DW, MacDougald OA, Richardson NE, Lamming DW, Kern PA, Alexander CM. Contrasting recruitment of skin-associated adipose depots during cold challenge of mouse and human. J Physiol. 2021 Mar 16; doi: 10.1113/JP280922. Epub 2021 Mar 16. PMID: 33724479; PMCID: PMC8443702.
Copy Download .nbib Format: NLM
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Multiple sclerosis and related disorders

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G, Macdougall A, Schmierer K, Hobart J, Gnanapavan S.
PMID: 34871856
Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22.

BACKGROUND: In multiple sclerosis (MS) neurofilament light chain (NfL) is a marker of neuronal damage secondary to inflammation and neurodegeneration. NfL levels drop after commencement of disease-modifying treatment, especially the highly active ones. However, the factors that influence this...

Cite
Smets I, Holden D, Bianchi L, et al. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021;57:103409doi: 10.1016/j.msard.2021.103409.
Smets, I., Holden, D., Bianchi, L., Ammoscato, F., Allen-Philbey, K., Baker, D., Turner, B., Marta, M., Giovannoni, G., Macdougall, A., Schmierer, K., Hobart, J., & Gnanapavan, S. (2021). Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple sclerosis and related disorders, 57103409. https://doi.org/10.1016/j.msard.2021.103409
Smets, Ide, et al. "Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study." Multiple sclerosis and related disorders vol. 57 (2021): 103409. doi: https://doi.org/10.1016/j.msard.2021.103409
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G, Macdougall A, Schmierer K, Hobart J, Gnanapavan S. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22. PMID: 34871856.
Copy Download .nbib Format: NLM
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.

Multiple sclerosis and related disorders

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R.
PMID: 34902760
Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04.

BACKGROUND: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging reports suggest that 1-3% B-cell repopulation facilitates seroconversion after...

Cite
Baker D, MacDougall A, Kang AS, et al. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021;57:103448doi: 10.1016/j.msard.2021.103448.
Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple sclerosis and related disorders, 57103448. https://doi.org/10.1016/j.msard.2021.103448
Baker, David, et al. "CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis." Multiple sclerosis and related disorders vol. 57 (2021): 103448. doi: https://doi.org/10.1016/j.msard.2021.103448
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04. PMID: 34902760; PMCID: PMC8642825.
Copy Download .nbib Format: NLM
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.

Multiple sclerosis and related disorders

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R.
PMID: 34902760
Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04.

BACKGROUND: Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2 vaccination unlike that seen following alemtuzumab and cladribine treatment. Emerging reports suggest that 1-3% B-cell repopulation facilitates seroconversion after...

Cite
Baker D, MacDougall A, Kang AS, et al. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021;57:103448doi: 10.1016/j.msard.2021.103448.
Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple sclerosis and related disorders, 57103448. https://doi.org/10.1016/j.msard.2021.103448
Baker, David, et al. "CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis." Multiple sclerosis and related disorders vol. 57 (2021): 103448. doi: https://doi.org/10.1016/j.msard.2021.103448
Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Mult Scler Relat Disord. 2021 Dec 04;57:103448. doi: 10.1016/j.msard.2021.103448. Epub 2021 Dec 04. PMID: 34902760; PMCID: PMC8642825.
Copy Download .nbib Format: NLM
A study of SPECT/CT camera stability for quantitative imaging.

EJNMMI physics

McDougald WA, Miyaoka RS, Alessio AM, Harrison RL, Lewellen TK.
PMID: 27473290
EJNMMI Phys. 2016 Dec;3(1):14. doi: 10.1186/s40658-016-0150-7. Epub 2016 Jul 29.

BACKGROUND: The purpose of this study was twofold: to evaluate the quantitative stability of a SPECT/CT gamma camera over time and to determine if daily flood acquisitions can reliably serve as calibration factors for quantitative SPECT. Using a cylindrical...

Cite
McDougald WA, Miyaoka RS, Alessio AM, et al. A study of SPECT/CT camera stability for quantitative imaging. EJNMMI Phys. 2016;3(1):14doi: 10.1186/s40658-016-0150-7.
McDougald, W. A., Miyaoka, R. S., Alessio, A. M., Harrison, R. L., & Lewellen, T. K. (2016). A study of SPECT/CT camera stability for quantitative imaging. EJNMMI physics, 3(1), 14. https://doi.org/10.1186/s40658-016-0150-7
McDougald, Wendy A, et al. "A study of SPECT/CT camera stability for quantitative imaging." EJNMMI physics vol. 3,1 (2016): 14. doi: https://doi.org/10.1186/s40658-016-0150-7
McDougald WA, Miyaoka RS, Alessio AM, Harrison RL, Lewellen TK. A study of SPECT/CT camera stability for quantitative imaging. EJNMMI Phys. 2016 Dec;3(1):14. doi: 10.1186/s40658-016-0150-7. Epub 2016 Jul 29. PMID: 27473290; PMCID: PMC4967048.
Copy Download .nbib Format: NLM
Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues.

Nature communications

Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA.
PMID: 27929114
Nat Commun. 2016 Dec 08;7:13775. doi: 10.1038/ncomms13775.

No abstract available.

Cite
Scheller EL, Doucette CR, Learman BS, et al. Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun. 2016;7:13775doi: 10.1038/ncomms13775.
Scheller, E. L., Doucette, C. R., Learman, B. S., Cawthorn, W. P., Khandaker, S., Schell, B., Wu, B., Ding, S. Y., Bredella, M. A., Fazeli, P. K., Khoury, B., Jepsen, K. J., Pilch, P. F., Klibanski, A., Rosen, C. J., & MacDougald, O. A. (2016). Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nature communications, 713775. https://doi.org/10.1038/ncomms13775
Scheller, Erica L, et al. "Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues." Nature communications vol. 7 (2016): 13775. doi: https://doi.org/10.1038/ncomms13775
Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY, Bredella MA, Fazeli PK, Khoury B, Jepsen KJ, Pilch PF, Klibanski A, Rosen CJ, MacDougald OA. Corrigendum: Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun. 2016 Dec 08;7:13775. doi: 10.1038/ncomms13775. PMID: 27929114; PMCID: PMC5155156.
Copy Download .nbib Format: NLM
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

The New England journal of medicine

George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA.
PMID: 34788507
N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205.

BACKGROUND: The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector dose.METHODS: In this phase 1-2 trial, we...

Cite
George LA, Monahan PE, Eyster ME, et al. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021;385(21):1961-1973doi: 10.1056/NEJMoa2104205.
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., Jaworski, K., Noble, R., Curran, M., Kuranda, K., Mingozzi, F., Chang, T., Reape, K. Z., Anguela, X. M., & High, K. A. (2021). Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. The New England journal of medicine, 385(21), 1961-1973. https://doi.org/10.1056/NEJMoa2104205
George, Lindsey A, et al. "Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A." The New England journal of medicine vol. 385,21 (2021): 1961-1973. doi: https://doi.org/10.1056/NEJMoa2104205
George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205. PMID: 34788507.
Copy Download .nbib Format: NLM
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study.

Multiple sclerosis and related disorders

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G, Macdougall A, Schmierer K, Hobart J, Gnanapavan S.
PMID: 34871856
Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22.

BACKGROUND: In multiple sclerosis (MS) neurofilament light chain (NfL) is a marker of neuronal damage secondary to inflammation and neurodegeneration. NfL levels drop after commencement of disease-modifying treatment, especially the highly active ones. However, the factors that influence this...

Cite
Smets I, Holden D, Bianchi L, et al. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021;57:103409doi: 10.1016/j.msard.2021.103409.
Smets, I., Holden, D., Bianchi, L., Ammoscato, F., Allen-Philbey, K., Baker, D., Turner, B., Marta, M., Giovannoni, G., Macdougall, A., Schmierer, K., Hobart, J., & Gnanapavan, S. (2021). Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple sclerosis and related disorders, 57103409. https://doi.org/10.1016/j.msard.2021.103409
Smets, Ide, et al. "Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study." Multiple sclerosis and related disorders vol. 57 (2021): 103409. doi: https://doi.org/10.1016/j.msard.2021.103409
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G, Macdougall A, Schmierer K, Hobart J, Gnanapavan S. Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Mult Scler Relat Disord. 2021 Nov 22;57:103409. doi: 10.1016/j.msard.2021.103409. Epub 2021 Nov 22. PMID: 34871856.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 75 entries